VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD

Llano, Daniel A.; Devanarayan, Priya; Devanarayan, Viswanath

doi:10.1097/wad.0000000000000328

Cited by 35Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD

Open access

Llano, Daniel A., Devanarayan, Priya, Devanarayan, Viswanath·2019·Alzheimer Disease & Associated Disorders

DOI 10.1097/wad.0000000000000328

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Previous work has suggested that the brain and cerebrospinal fluid (CSF) levels of a neural protein involved in synaptic transmission, VGF (a noninitialism), may be altered in mild cognitive impairment (MCI) and Alzheimer Disease (AD). The objective of the current work is to examine the potential of CSF levels of a peptide derived from VGF to predict conversion from MCI to AD. MATERIALS AND METHODS: Using multivariate analytical approaches, the performance of the conventional biomarkers (CSF Aβ1-42 and phosphorylated tau +/- hippocampal volume) was compared with the same biomarkers combined with CSF VGF peptide levels in a large publicly available data set from human subjects. RESULTS: It was observed that VGF peptides are lowered in CSF of patients with AD compared with controls and that combinations of CSF Aβ1-42 and phosphorylated tau, hippocampal volume, and VGF peptide levels outperformed conventional biomarkers alone (hazard ratio=2.2 vs. 3.9), for predicting MCI to AD conversion. CONCLUSIONS: CSF VGF enhances the ability of conventional biomarkers to predict MCI to AD conversion. Future work will be needed to determine the specificity of VGF for AD versus other neurodegenerative diseases.

Integrity signals

Registry

Crossref · 10.1097/wad.0000000000000328

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Four proteins (GPNMB, SMOC1, NPTX2, VGF) were previously reported in AD CSF.
“In the list, 4 proteins (GPNMB, SMOC1, NPTX2 and VGF) have previously been reported in AD CSF (Dayon et al., 2018; Huttenrauch et al., 2018; Llano et al., 2019; Xiao et al., 2017)”
From Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression (2020) · cites this paper as Llano et al., 2019
The battery of exams for early AD diagnosis would cost several thousands of Euros/US dollars per individual case, a burden not affordable by any worldwide health systems, and is somewhat invasive and not widely available.
“However, this battery of exams would cost several thousands of Euros/US dollars per individual case—a burden not affordable by any of the worldwide health systems—besides being somewhat invasive and not widely available (due to the highly sophisticated technologies required) in several countries.”
From Early dementia diagnosis, MCI-to-dementia risk prediction, and the role of machine learning methods for feature extraction from integrated biomarkers, in particular for EEG signal analysis (2022) · cites this paper as [15]

Cortical Surface-Based Analysis
Dale, A. M., Fischl, B., & Sereno, M. I. (1999) · NeuroImage · doi:10.1006/nimg.1998.0395 · Cited by 10,910 · see citing works
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works
Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · see citing works
Cortical Surface-Based Analysis
Fischl, B., Sereno, M. I., & Dale, A. M. (1999) · NeuroImage · doi:10.1006/nimg.1998.0396 · Cited by 6,147 · see citing works
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · see citing works
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works
Untitled work
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · see citing works
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · see citing works
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · see citing works
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
Jack, C. R., Petersen, R. C., Xu, Y. C., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Waring, S. C., Tangalos, E. G., & Kokmen, E. (1999) · Neurology · doi:10.1212/wnl.52.7.1397 · Cited by 1,404 · see citing works
Risk Factors for Alzheimer's Disease: A Prospective Analysis from the Canadian Study of Health and Aging
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · see citing works
Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · see citing works
Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD
Dickerson, B. C., Salat, D. H., Greve, D. N., Chua, E. F., Rand-Giovannetti, E., Rentz, D. M., Bertram, L., Mullin, K., Tanzi, R. E., Blacker, D., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000171450.97464.49 · Cited by 910 · see citing works
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · see citing works
The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
Sengupta, U., Nilson, A. N., & Kayed, R. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.035 · Cited by 740 · see citing works
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702 · see citing works
Reduction of β‐amyloid peptide<sub>42</sub> in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort
Risacher, S., Saykin, A., Wes, J., Shen, L., Firpi, H., & McDonald, B. (2009) · Current Alzheimer Research · doi:10.2174/156720509788929273 · Cited by 538 · see citing works
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01697-9 · Cited by 450 · see citing works
High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype
Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442 · see citing works
MRI and CSF biomarkers in normal, MCI, and AD subjects
Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79fb · Cited by 398 · see citing works
A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease
Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G. L., Burkhard, P. R., Hochstrasser, D. F., & Sanchez, J. (2003) · PROTEOMICS · doi:10.1002/pmic.200300470 · Cited by 375 · see citing works
Accelerated Weight Loss May Precede Diagnosis in Alzheimer Disease
Johnson, D. K., Wilkins, C. H., & Morris, J. C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.9.1312 · Cited by 339 · see citing works
Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion
Westman, E., Muehlboeck, J., & Simmons, A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.04.056 · Cited by 304 · see citing works
Brain-Derived Neurotrophic Factor-Induced Gene Expression Reveals Novel Actions of VGF in Hippocampal Synaptic Plasticity
Alder, J., Thakker‐Varia, S., Bangasser, D. A., Kuroiwa, M., Plummer, M. R., Shors, T. J., & Black, I. B. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10800.2003 · Cited by 303 · see citing works
Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment
Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001473 · Cited by 287 · see citing works
Weight loss in Alzheimer disease
Guyonnet, S., Nourhashémi, F., Andrieu, S., de Glisezinski, I., Ousset, P., Rivière, D., Albaréde, J. L., & Vellas, B. J. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.637s · Cited by 283 · see citing works
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
Drzezga, A. E., Grimmer, T., Riemenschneider, M., Lautenschlager, N. T., Siebner, H. R., Alexopoulus, P., Minoshima, S., Schwaiger, M., & Kurz, A. (2005) · PubMed · Cited by 277 · see citing works
CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease
Westin, K., Buchhave, P., Nielsen, H., Minthon, L., Janciauskiene, S., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030525 · Cited by 277 · see citing works
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Kester, M. I., Teunissen, C. E., Crimmins, D. L., Herries, E. M., Ladenson, J. H., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1867 · Cited by 246 · see citing works
Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis
Craig‐Schapiro, R., Kühn, M., Xiong, C., Pickering, E. H., Liu, J., Misko, T. P., Perrin, R. J., Bales, K. R., Soares, H. D., Fagan, A. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018850 · Cited by 235 · see citing works
Targeted Deletion of the Vgf Gene Indicates that the Encoded Secretory Peptide Precursor Plays a Novel Role in the Regulation of Energy Balance
Hahm, S., Mizuno, T. M., Wu, T. J., Wisor, J. P., Priest, C. A., Kozak, C. A., Boozer, C. N., Peng, B. W., McEvoy, R. C., Good, P., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80806-5 · Cited by 223 · see citing works
Diagnostic Performance of Cerebrospinal Fluid Total Tau and Phosphorylated Tau in Creutzfeldt-Jakob Disease: Results From the Swedish Mortality Registry
Skillbäck, T., Rosén, C., Asztely, F., Mattsson, N., Blennow, K., & Zetterberg, H. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6455 · Cited by 207 · see citing works
Predicting MCI outcome with clinically available MRI and CSF biomarkers
Heister, D. S., Brewer, J. B., Magda, S., Blennow, K., McEvoy, L. K., & Initiative, A. D. N. (2011) · Neurology · doi:10.1212/wnl.0b013e3182343314 · Cited by 201 · see citing works
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment
Bouwman, F. H., Schoonenboom, S. N. M., van der Flier, W. M., van Elk, E. J., Kok, A., Barkhof, F., Blankenstein, M. A., & Scheltens, P. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.006 · Cited by 175 · see citing works
Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease
Perrin, R. J., Craig‐Schapiro, R., Malone, J. P., Shah, A. R., Erdmann-Gilmore, P., Davis, A., Roe, C. M., Peskind, E. R., Li, G., Galasko, D. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016032 · Cited by 172 · see citing works
Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature
Diniz, B. S., Pinto, J. A., & Forlenza, O. V. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701535502 · Cited by 168 · see citing works
The Neuropeptide VGF Produces Antidepressant-Like Behavioral Effects and Enhances Proliferation in the Hippocampus
Thakker‐Varia, S., Krol, J. G., Nettleton, J., Bilimoria, P. M., Bangasser, D. A., Shors, T. J., Black, I. B., & Alder, J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1898-07.2007 · Cited by 166 · see citing works
VGF: A Novel Role for This Neuronal and Neuroendocrine Polypeptide in the Regulation of Energy Balance
Salton, S. R., Ferri, G., Hahm, S., Snyder, S. E., Wilson, A. J., Possenti, R., & Levi, A. (2000) · Frontiers in Neuroendocrinology · doi:10.1006/frne.2000.0199 · Cited by 163 · see citing works
Cerebrospinal fluid markers for prediction of Alzheimer's disease
Zetterberg, H., Wahlund, L., & Blennow, K. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.08.011 · Cited by 162 · see citing works
Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF
Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., Baker, D., Raghavan, N., Nairn, A. C., Croteau, P., Schirm, M., Allard, R., et al. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400178 · Cited by 161 · see citing works
Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
Heywood, W., Galimberti, D., Bliss, E., Sirka, E., Paterson, R. W., Magdalinou, N. K., Carecchio, M., Reid, E. S., Heslegrave, A., Fenoglio, C., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0059-y · Cited by 159 · see citing works
The Neurotrophin-Inducible Gene Vgf Regulates Hippocampal Function and Behavior through a Brain-Derived Neurotrophic Factor-Dependent Mechanism
Bozdagi, O., Rich, E. L., Tronel, S., Sadahiro, M., Patterson, K., Shapiro, M. L., Alberini, C. M., Huntley, G. W., & Salton, S. R. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3145-08.2008 · Cited by 145 · see citing works
Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design
van Rossum, I. A., Vos, S. J. B., Handels, R. L. H., & Visser, P. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091606 · Cited by 143 · see citing works
Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype
Blom, E. S., Giedraitis, V., Zetterberg, H., Fukumoto, H., Blennow, K., Hyman, B. T., Irizarry, M. C., Wahlund, L., Lannfelt, L., & Ingelsson, M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000216841 · Cited by 141 · see citing works
Processing, Distribution, and Function of VGF, a Neuronal and Endocrine Peptide Precursor
Levi, A., Ferri, G., Watson, E., Possenti, R., & Salton, S. R. (2004) · Cellular and Molecular Neurobiology · doi:10.1023/b:cemn.0000023627.79947.22 · Cited by 141 · see citing works
Cerebrospinal fluid tau, phospho‐tau181 and β‐amyloid1−42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease
Kapaki, E., Paraskevas, G. P., Tzerakis, N. G., Sfagos, C., Seretis, A., Kararizou, E., & Vassilopoulos, D. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01593.x · Cited by 140 · see citing works
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
Wildsmith, K. R., Schauer, S. P., Smith, A. M., Arnott, D. P., Zhu, Y., Haznedar, J., Kaur, S., Mathews, W. R., & Honigberg, L. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-22 · Cited by 140 · see citing works
WHY ARE ALZHEIMER PATIENTS THIN?
Singh, S., Mulley, G. P., & Losowsky, M. S. (1988) · Age and Ageing · doi:10.1093/ageing/17.1.21 · Cited by 137 · see citing works
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
Duits, F. H., Brinkmalm, G., Teunissen, C. E., Brinkmalm, A., Scheltens, P., Van der Flier, W. M., Zetterberg, H., & Blennow, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0335-x · Cited by 137 · see citing works
Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
Sämgård, K., Zetterberg, H., Blennow, K., Hansson, O., Minthon, L., & Londos, E. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2353 · Cited by 133 · see citing works
Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF
Rüetschi, U., Zetterberg, H., Podust, V. N., Gottfries, J., Li, S., Simonsen, A. H., McGuire, J., Karlsson, M., Rymo, L., Davies, H., et al. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.08.002 · Cited by 129 · see citing works
CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies
Mitchell, A. J. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.167791 · Cited by 123 · see citing works
Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic Biomarkers
Jahn, H., Wittke, S., Zürbig, P., Raedler, T. J., Arlt, S., Kellmann, M., Mullen, W., Eichenlaub, M., Mischak, H., & Wiedemann, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026540 · Cited by 116 · see citing works
A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease
Brinkmalm, G., Sjödin, S., Simonsen, A. H., Hasselbalch, S. G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2018) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201700131 · Cited by 111 · see citing works
Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
Forlenza, O. V., Radanovic, M., Talib, L. L., Aprahamian, I., Diniz, B. S., Zetterberg, H., & Gattaz, W. F. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.003 · Cited by 110 · see citing works
Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease
Roher, A. E., Maarouf, C. L., Sue, L. I., Hu, Y., Wilson, J. R., & Beach, T. G. (2009) · Biomarkers · doi:10.3109/13547500903108423 · Cited by 108 · see citing works
An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics—Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease
Hölttä, M., Minthon, L., Hansson, O., Holmén-Larsson, J., Pike, I., Ward, M., Kuhn, K., Rüetschi, U., Zetterberg, H., Blennow, K., et al. (2015) · Journal of Proteome Research · doi:10.1021/pr501076j · Cited by 100 · see citing works
Accuracy of Clinical Diagnosis of Alzheimer Disease and Clinical Features of Patients with Non-Alzheimer Disease Neuropathology
Rasmusson, D. X., Brandt, J., Steele, C., Hedreen, J. C., Troncoso, J. C., & Folstein, M. F. (1996) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199601040-00002 · Cited by 93 · see citing works
Distribution of VGF peptides in the human cortex and their selective changes in Parkinson’s and Alzheimer’s diseases
Cocco, C., D’Amato, F., Noli, B., Ledda, A., Brancia, C., Bongioanni, P., & Ferri, G. (2010) · Journal of Anatomy · doi:10.1111/j.1469-7580.2010.01309.x · Cited by 75 · see citing works
Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid1–42 in the Differentiation between Alzheimer’s Disease and Vascular Dementia
Nägga, K., Gottfries, J., Blennow, K., & Marcusson, J. O. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000066023 · Cited by 71 · see citing works
Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease
Llano, D. A., Devanarayan, V., & Simon, A. J. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31826d597a · Cited by 70 · see citing works
Self-citation
High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid
Hendrickson, R. C., Lee, A. Y. H., Song, Q., Liaw, A. I., Wiener, M., Paweletz, C. P., Seeburger, J. L., Li, J., Meng, F., Deyanova, E. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135365 · Cited by 68 · see citing works
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology
Paterson, R., Heywood, W., Heslegrave, A., Magdalinou, N., Andreasson, U., Sirka, E., Bliss, E., Slattery, C., Toombs, J., Svensson, J., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.194 · Cited by 65 · see citing works
VGF (TLQP-62)-induced neurogenesis targets early phase neural progenitor cells in the adult hippocampus and requires glutamate and BDNF signaling
Thakker‐Varia, S., Behnke, J. A., Doobin, D. J., Dalal, V., Thakkar, K., Khadim, F., Wilson, E., Palmieri, A. J., Antila, H., Rantamäki, T., et al. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.03.005 · Cited by 64 · see citing works
14-3-3 Protein, Total Tau and Phosphorylated Tau in Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease and Neurodegenerative Disease in Japan
Satoh, K., Shirabe, S., Eguchi, H., et al. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9370-z · Cited by 64 · see citing works
CSF Levels of Heart Fatty Acid Binding Protein are Altered During Early Phases of Alzheimer's Disease
Chiasserini, D., Parnetti, L., Andréasson, U., Zetterberg, H., Giannandrea, D., Calabresi, P., & Blennow, K. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101293 · Cited by 63 · see citing works
Identification of Novel Biomarker Candidates by Differential Peptidomics Analysis of Cerebrospinal Fluid in Alzheimers Disease
Selle, H., Lamerz, J., Büerger, K., Dessauer, A., Häger, K., Hampel, H. J., Karl, J., Kellmann, M., Lannfelt, L., Louhija, J., et al. (2005) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620705774962391 · Cited by 62 · see citing works
Patient subgroup identification for clinical drug development
Huang, X., Sun, Y., Trow, P. B., Chatterjee, S., Chakravartty, A., Tian, L., & Devanarayan, V. (2017) · Statistics in Medicine · doi:10.1002/sim.7236 · Cited by 60 · see citing works
Self-citation
The messenger RNA encoding VGF, a neuronal peptide precursor, is rapidly regulated in the rat central nervous system by neuronal activity, seizure and lesion
Snyder, S. E., Cheng, H. W., Murray, K. D., Isackson, P. J., McNeill, T. H., & Salton, S. R. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00280-7 · Cited by 56 · see citing works
A novel peptidomics approach to detect markers of Alzheimer’s disease in cerebrospinal fluid
Wijte, D., McDonnell, L. A., Balog, C. I. A., Bossers, K., Deelder, A. M., Swaab, D. F., Verhaagen, J., & Mayboroda, O. A. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.018 · Cited by 51 · see citing works
A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression
Llano, D. A., Bundela, S., Mudar, R. A., Devanarayan, V., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182098 · Cited by 51 · see citing works
Self-citation
A PRIM approach to predictive‐signature development for patient stratification
Chen, G., Zhong, J., Belousov, A., & Devanarayan, V. (2014) · Statistics in Medicine · doi:10.1002/sim.6343 · Cited by 50 · see citing works
Self-citation
GABAB receptor gene expression in monkey thalamus
Mu�oz, A., Huntsman, M. M., & Jones, E. G. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980427)394:1 · Cited by 48 · see citing works
Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates
Choi, Y. S., Hou, S., Choe, L. H., & Lee, K. H. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.05.003 · Cited by 47 · see citing works
Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia
Olsson, B., Hertze, J., Ohlsson, M., Nägga, K., Höglund, K., Basun, H., Annas, P., Lannfelt, L., Andreasen, N., Minthon, L., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121384 · Cited by 46 · see citing works
The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis
Bartosik-Psujek, H., & Stelmasiak, Z. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0327-z · Cited by 45 · see citing works
Proteomic Analysis of Cerebrospinal Fluid in Alzheimer's Disease: Wanted Dead or Alive
Galik-Olah, Z., Kalman, J. L., Tóth, M. E., Zvara, Á., Sántha, M., Ivitz, E., Janka, Z., & Pákáski, M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-140141 · Cited by 43 · see citing works
Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers
Handels, R. L. H., Vos, S. J. B., Kramberger, M. G., Jelić, V., Blennow, K., van Buchem, M. A., van der Flier, W. M., Freund‐Levi, Y., Hampel, H. J., Rikkert, M. G. M. O., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.015 · Cited by 41 · see citing works
Enriching Amnestic Mild Cognitive Impairment Populations for Clinical Trials: Optimal Combination of Biomarkers to Predict Conversion to Dementia
Yu, P., Initiative, A. D. N., Dean, R. A., Hall, S. D., Qi, Y., Sethuraman, G., Willis, B. A., Siemers, E., Martényi, F., Tauscher, J. T., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120832 · Cited by 39 · see citing works
Proteomic Analysis of Alzheimers Disease Cerebrospinal Fluid from Neuropathologically Diagnosed Subjects
Maarouf, C. L., Andacht, T. M., Kokjohn, T. A., Castaño, E. M., Sue, L. I., Beach, T. G., & Roher, A. E. (2009) · Current Alzheimer Research · doi:10.2174/156720509788929318 · Cited by 34 · see citing works
Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
Lanari, A., & Parnetti, L. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.106 · Cited by 32 · see citing works
Body composition of patients with Alzheimer's disease
Renvall, M. J., Spindler, A. A., Nichols, J. F., & Ramsdell, J. (1993) · Journal of the American Dietetic Association · doi:10.1016/0002-8223(93)92130-p · Cited by 28 · see citing works
Combined use of biochemical and volumetric biomarkers to assess the risk of conversion of mild cognitive impairment to Alzheimer’s disease
Nesteruk, M., Nesteruk, T., Styczyńska, M., Mandecka, M., Barczak, A. K., & Barcikowska, M. (2016) · Folia Neuropathologica · doi:10.5114/fn.2016.64815 · Cited by 19 · see citing works
Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer’s Disease Progression that Reinforces the 2018 NIA-AA Research Framework
Devanarayan, P., Devanarayan, V., Llano, D. A., & (ADNI), T. A. D. N. I. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180905 · Cited by 18 · see citing works
Self-citation
O3‐04‐06: Misdiagnosis of Alzheimer's Disease: Inconsistencies Between Clinical Diagnosis and Neuropathological Confirmation
Qian, W., Schweizer, T. A., Muñoz, D. G., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.529 · Cited by 16 · see citing works
Multiscale causal network models of Alzheimer’s disease identify VGF as a key regulator of diseasePreprint
Beckmann, N. D., Lin, W., Wang, M., Cohain, A. T., Wang, P., Ma, W., Wang, Y., Jiang, C. S., Audrain, M., Comella, P., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/458430 · Cited by 12 · see citing works
DT‐02–04: Excess costs associated with misdiagnosis of Alzheimer's disease among U.S. Medicare beneficiaries with vascular dementia or Parkinson's disease
Kirson, N. Y., Hunter, C., Desai, U. S., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.08.011 · Cited by 6 · see citing works
Identification of a simple and novel cut-point based CSF and MRI signature for predicting Alzheimer’s disease progression that reinforces the 2018 NIA-AA research framework
(2018) · doi:10.1101/443325 · Cited by 1 · see citing works
High-resolution intersubject averaging and a coordinate system for the cortical surface
Fischl, B., Sereno, M. I., Tootell, R. B. H., & Dale, A. M. (1999) · Human Brain Mapping · doi:10.1002/(sici)1097-0193(1999)8:4

Flagged first, then by citations

Sorted by citations

Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression
Bai, B., Wang, X., Li, Y., Chen, P.-C., Yu, K., Dey, K. K., Yarbro, J. M., Han, X., Lutz, B. M., Rao, S., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.015 · Cited by 632 · see citing works
Early dementia diagnosis, MCI-to-dementia risk prediction, and the role of machine learning methods for feature extraction from integrated biomarkers, in particular for EEG signal analysis
Rossini, P. M., Miraglia, F., & Vecchio, F. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12645 · Cited by 93 · see citing works
Prediction of progression from mild cognitive impairment to Alzheimer's disease with longitudinal and multimodal data
Ding, H., Wang, B., Hamel, A. P., Melkonyan, M., Ang, T. F. A., Au, R., & Lin, H. (2023) · Frontiers in Dementia · doi:10.3389/frdem.2023.1271680 · Cited by 32 · see citing works
Intracerebral Nanoparticle Transport Facilitated by Alzheimer Pathology and Age
Tracy, G. C., Huang, K.-Y., Hong, Y.-T., Ding, S., Noblet, H. A., Lim, K. H., Kim, E. C., Chung, H. J., & Kong, H. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c03222 · Cited by 24 · see citing works

Cerebrospinal fluid endothelin-1 in Alzheimer's disease and senile dementia of Alzheimer type
Yoshizawa, T., Iwamoto, H., Mizusawa, H., et al. (1992) · Neuropeptides · doi:10.1016/0143-4179(92)90059-6 · Cited by 20 · see citing works
Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease
Shetty, H. U., Holloway, H. W., & Schapiro, M. B. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.2.298 · Cited by 33 · see citing works
Lack of Genetic Associations of Alpha-1-Antichymotrypsin Polymorphism with Alzheimer-Type Neuropathological Changes or Sporadic Alzheimer’s Disease
Sodeyama, N., Yamada, M., Itoh, Y., Suematsu, N., Matsushita, M., Otomo, E., & Mizusawa, H. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017123 · Cited by 11 · see citing works
Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer's disease patients
Rösler, N., Wichart, I., & Jellinger, K. A. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01514-2 · Cited by 20 · see citing works
Apoptosis in neurones exposed to cerebrospinal fluid from patients with multiple sclerosis or acute polyradiculoneuropathy
Øren, A., White, L. R., & Aasly, J. O. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00496-8 · Cited by 8 · see citing works

Authors: Llano, D. A., Devanarayan, P., & Devanarayan, V.
Affiliations: University of Illinois Urbana-Champaign (US)
Souderton Area High School, Souderton
University of Illinois Chicago (US)
Corresponding author: Llano, Daniel A.
ORCID: Llano, Daniel A.
Devanarayan, Viswanath
Venue: Alzheimer Disease & Associated Disorders
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2019-10
Volume: 33
Issue: 4
Pages: 307-314
ISSN: 0893-0341 (ISSN-L)
DOI: 10.1097/wad.0000000000000328
OpenAlex: W2957495611
Cited by: 35
References: 93
Citations by year: 2026: 2 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 2 · 2020: 7 · 2019: 2
FWCI: 3.78
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by
Locations: Alzheimer Disease & Associated Disorders (publishedVersion)
bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
PubMed (publishedVersion)
Funders: U.S. Department of Defense (U01 AG024904, W81XWH, W81XWH-12-2-, W81XWH-12, AG024904)
Alzheimer's Association (U01 AG024904, W81XWH-12-2-0012)
Biogen (W81XWH-12-2-0012, U01 AG024904, AG024904)
Alzheimer's Disease Neuroimaging Initiative (W81XWH-12-2–0012, U01AG024904, AG024904, W81XWH-12-2-)
BioClinica (U01 AG024904, W81XWH-12-2-0012, AG024904)
National Institutes of Health (W81XWH, W81XWH-12-2-0012, U01-AG024904, AG024904)
University of California, Davis
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
Keywords: VGF, cerebrospinal fluid biomarkers, mild cognitive impairment, Alzheimer's disease, conversion prediction, amyloid-beta 42, phosphorylated tau, hippocampal volume, combined biomarker detection, neurodegeneration
MeSH terms: Aged, Alzheimer Disease, Brain, Female, Hippocampus, Humans, Male, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks